Katharina Prestin

2 papers in the library · 52 citations · publishing 2016-2017

Papers

Sort Most recent Most cited

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.

European Neuropsychopharmacology March 2017 Patrick Vizeli, Yasmin Schmid, Katharina Prestin et al.

In vitro studies showed that CYP2C19, CYP2B6, and CYP1A2 contribute to the metabolism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to 3,4-methylenedioxyamphetamine (MDA). However, the role of genetic polymorphisms in CYP2C19, CYP2B6, and CYP1A2 in the metabolism of MDMA in humans is unknown. The effects of genetic variants in these CYP enzymes on the pharmacokinetics and...

DOI: 10.1016/j.euroneuro.2017.01.008 Full text 3,4-methylenedioxyamphetamine 3,4-methylenedioxymethamphetamine Cyp1a2 Cyp2b6 +2

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Pharmacogenetics and Genomics June 2, 2016 Yasmin Schmid, Patrick Vizeli, Cédric M. Hysek et al. 52 citations

The role of genetic polymorphisms in cytochrome (CYP) 2D6 involved in the metabolism of 3,4-methylene-dioxymethamphetamine (MDMA, ecstasy) is unclear. Effects of genetic variants in CYP2D6 on the pharmacokinetics and pharmacodynamic effects of MDMA were characterized in 139 healthy individuals (70 men, 69 women) in a pooled analysis of eight double-blind, placebo-controlled crossover studies....

DOI: 10.1097/fpc.0000000000000231 MDMA Ecstasy Cyp2d6 Pharmacology +10